Full-Time

Senior Manager

Regulatory Affairs

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$135k - $175kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Business Strategy
Requirements
  • Bachelor's Degree in a relevant field and at least 5 years of direct Regulatory experience.
  • Strong working knowledge of US FDA Pharmaceutical regulations and guidance.
  • Proven track record of successful submissions within a regulatory environment.
  • Exceptionally strong team player with excellent interpersonal and communication skills.
  • Detail-oriented with strong organizational skills and high-quality standards.
  • Knowledge of EU EMA Pharmaceutical regulations and guidance preferred.
  • Direct experience with IND/NDA filings.
Responsibilities
  • Manage planning, preparation, coordination, and submission of regulatory documents to global National Health Authorities. Such submissions may include Clinical, Preclinical, or CMC content.
  • Correspond and collaborate with RevMed colleagues and departments to achieve alignment.
  • Function as a Regulatory Affairs subject matter expert member of cross-functional teams, including study teams and submission teams.
  • Perform regulatory research to inform business strategy. Assess and communicate risks.
  • Assure that there are no significant interruptions to the business due to regulatory compliance issues.
  • Collaborates across the organization at all levels, across functional groups, and with executive management.
  • Develop regulatory strategies to inform associated budgets, tools and specialized support necessary for efficient operations.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?